Clinical Trials Sponsored by FluidDA nv

Total 339 results

Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease (Divergence2)

Fistulizing Crohn's Disease

United States, Italy, Belgium, Austria, Canada, Hungary, United Kingdom, Germany, France
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy (PENGUIN 2)

Psoriatic Arthritis

Korea, Republic of, United States, Australia, Belgium, Canada, Czechia, Hungary, Japan, Poland, Spain, Taiwan
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis (HUMBOLDT)

Noninfectious Uveitis

United States, Israel, United Kingdom, Germany, Australia, Canada, New Zealand
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD) (DIVERGENCE 1)

Small Bowel Crohn's Disease

United States, Belgium, United Kingdom, Germany, Spain, Czechia, Canada, Austria, France, Hungary, Italy, Ukraine
Gilead Sciences
Galapagos NV

Completed

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment (FINCH 2)

Rheumatoid Arthritis

United States, France, Germany, Spain, Israel, Japan, Korea, Republic of, Belgium, Argentina, Poland, Hungary, United Kingdom, Mexico, Australia, Switzerland
Janssen-Cilag International NV

Completed

A Study to Determine the Epidemiology and Evaluate the Burden of Disease in Respiratory Syncytial Virus/Human Metapneumovirus and Influenza A Infected Hospitalized Participants (Adults and Children)

Respiratory Tract Infections

Germany, Spain
Janssen-Cilag International NV

Withdrawn

A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

Depressive Disorder, Treatment-Resistant
Janssen-Cilag International NV

Completed

A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly

Schizophrenia

Germany, Spain, Belgium, Hungary, France, Italy, United Kingdom
Janssen-Cilag International NV

Completed

A Study to Investigate P2X7 Receptor Occupancy by JNJ-54175446 With the Newly Developed P2X7 Receptor Positron Emission Tomography (PET) Tracer 18F-JNJ-64413739

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults

Healthy

Germany
Janssen-Cilag International NV

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274

Healthy

United Kingdom
Janssen-Cilag International NV

Completed

A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants

Healthy

Belgium
Galapagos NV
MorphoSys AG

Completed

First in Human of Single and Multiple Doses of MOR106

Healthy | Dermatitis, Atopic

Belgium, Hungary, Moldova, Republic of, Romania
Janssen-Cilag International NV

Completed

A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male Participants

Healthy Volunteers | Pharmacokinetics

Belgium
Janssen-Cilag International NV

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

Healthy

Germany
Janssen-Cilag International NV

Completed

An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan (CRATOS)

Diabetes Mellitus, Type 2

United Arab Emirates, Lebanon, Kuwait
Janssen-Cilag International NV

Completed

Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease. (PROFILE)

Gastroesophageal Reflux Disease | GERD | Gastro-oesophageal Reflux | Gastro-Esophageal Reflux | Esophageal Reflux
Janssen-Cilag International NV

Completed

Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Participants

Healthy

Netherlands
Janssen-Cilag International NV

No longer available

Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Hepatitis C

Australia, Belgium, Germany, Spain, Switzerland, Romania, Serbia, Greece, New Zealand, Brazil, Russian Federation, Austria, Hungary, Czech Republic, Luxembourg
Janssen-Cilag International NV

Completed

Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C

Genotype 1 Chronic Hepatitis C

Russian Federation
Therabel Pharma SA/NV

Completed

Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris (MEDCOR)

Atherosclerosis | Stable Angina Pectoris

Belgium
Janssen-Cilag International NV

Completed

A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers

Healthy

Germany
Janssen-Cilag International NV

Completed

InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics

Schizophrenia

France, Germany, Spain, South Africa, Turkey, Greece, Czech Republic, Russian Federation
Janssen-Cilag International NV

Completed

Effects of Canagliflozin on C-peptide Clearance in Healthy Volunteers

Healthy

Germany
Janssen-Cilag International NV

Completed

A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients (SENSE)

Acquired Immunodeficiency Syndrome | HIV Infection | HIV

France, United Kingdom, Germany, Spain, Switzerland, Israel, Russian Federation, Austria, Hungary, Romania, Denmark
Janssen-Cilag International NV

Completed

Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir (MONET)

HIV Infections | Human Immunodeficiency Virus | Acquired Immunodeficiency Syndrome Virus | AIDS Virus

United Kingdom, Belgium, Germany, Spain, Portugal, Israel, Denmark, Russian Federation, Austria, Hungary, Switzerland
Novosanis NV
Universiteit Antwerpen

Recruiting

Investigation of Urinary Biomarkers for the Detection of Breast Cancer (URODETECT-WP3)

Breast Cancer | Urine | Liquid Biopsy

Belgium
Janssen-Cilag International NV

Recruiting

A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis (STELARA)

Psoriasis

Belgium, United Kingdom, Austria, Denmark, France, Germany, Netherlands, Norway, Russian Federation, Switzerland, Greece
F Care Systems NV

Completed

Multicenter Prospective Evaluation of Radiofrequency for Anal Fistulas (RADIOFIST)

Anal Fistula

France
Galapagos NV
Gilead Sciences

Completed

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease (DIVERSITY1)

Crohn's Disease

Hong Kong, United States, Netherlands, Belgium, France, Israel, Spain, Korea, Republic of, Taiwan, Germany, Australia, United Kingdom, Italy, India, Singapore, Portugal, Malaysia, New Zealand, Serbia, Ireland, Poland, Romania, Japan, ... and more
Galapagos NV
Gilead Sciences

Terminated

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease (MANTA)

Inflammatory Bowel Disease

United States, Australia, India, Germany, United Kingdom, Russian Federation, New Zealand, Austria, Poland, Romania, Ukraine
Galapagos NV
Gilead Sciences

Active, not recruiting

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis (FINCH 4)

Rheumatoid Arthritis

Spain, United States, Japan, Korea, Republic of, Taiwan, Belgium, India, Malaysia, Argentina, Australia, Poland, Czechia, Serbia, Germany, New Zealand, Bulgaria, Canada, Chile, France, Hong Kong, Hungary, Ireland, Israel, Italy, Mexico, R... and more
Galapagos NV
Gilead Sciences

Terminated

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease (DIVERSITYLTE)

Crohn's Disease

Hong Kong, United States, Netherlands, Belgium, Israel, Spain, Korea, Republic of, Taiwan, Germany, Australia, Italy, India, Singapore, Portugal, France, Malaysia, New Zealand, Ireland, Poland, Romania, Japan, Croatia, Iceland, United... and more
Galapagos NV
Gilead Sciences

Completed

Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Patients (DARWIN3)

Rheumatoid Arthritis

New Zealand, Belgium, Israel, Chile, Argentina, Colombia, Spain, Australia, Latvia, Poland, Russian Federation, United States, Bulgaria, Czechia, France, Germany, Guatemala, Hungary, Mexico, Moldova, Republic of, Romania, Ukraine
Janssen-Cilag International NV

Completed

A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder

Major Depressive Disorder

Belgium, Germany, Netherlands
Gilead Sciences
Galapagos NV

Completed

Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy (FINCH 3)

Rheumatoid Arthritis

United States, Italy, Poland, Ukraine, Belgium, Hong Kong, Taiwan, Spain, Bulgaria, India, Malaysia, Romania, Serbia, South Africa, Korea, Republic of, Japan, Australia, Chile, Russian Federation, Argentina, Germany, New Zealand, Th... and more
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function

Rheumatoid Arthritis

United States, Germany, New Zealand
Gilead Sciences
Galapagos NV

Withdrawn

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy (SEALION2-NAÏVE)

Ankylosing Spondylitis
Janssen-Cilag International NV

Completed

A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment

Hepatic Impairment

Germany
Janssen-Cilag International NV

Completed

A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment (PROTEA)

Human Immunodeficiency Virus (HIV) Infections | Acquired Immunodeficiency Syndrome (AIDS) Virus

France, United Kingdom, Belgium, Germany, Spain, Switzerland, Denmark, Israel, Austria, Poland, Hungary, Sweden, Ireland
Janssen-Cilag International NV

Completed

A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet and Single Agent Concept Formulations of JNJ-63623872 Compared to Their Respective Reference Formulation in Healthy Adult Participants

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants (COMMIT)

Hepatitis C, Chronic

France, United Kingdom, Belgium, Spain, Germany, Hungary
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection

Hepatitis C

Egypt
Janssen-Cilag International NV

Completed

A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection

Hepatitis C, Chronic | Infection

United Kingdom, Germany, Spain, Belgium, Saudi Arabia, Austria, France
Janssen-Cilag International NV

Completed

Telaprevir Open-Label Study in Co-Infected Patients

Hepatitis C, Chronic

United Kingdom, Belgium, Germany, Portugal, Russian Federation, Hungary, Ireland, Luxembourg
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation (REPLACE)

Chronic Hepatitis C Virus (HCV) Infection

France, United Kingdom, Spain, Germany, Belgium, Austria

3

Subscribe